p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 12, 2005, Pages 675-677

  Papadhimitriou, Stefanos I ^a   Polychronopoulou, S ^b   Tsakiridou, A A ^a   Androutsos, G ^a   Paterakis, G S ^a   Athanassiadou, F ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Acute lymphoblastic leukemia; Childhood; p16; Prognosis; TEL AML1

Indexed keywords

HYBRID PROTEIN; PROTEIN P16INK4A; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CHROMOSOME 12; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 9P; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DISEASE COURSE; FATALITY; GENE DELETION; GENE INACTIVATION; HEMIZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW TRANSPLANTATION; CHILD; CHROMOSOMES, HUMAN, PAIR 9; COMBINED MODALITY THERAPY; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FATAL OUTCOME; GENE DELETION; GENES, P16; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PREDNISONE; PROGNOSIS; RECURRENCE; VINCRISTINE;

EID: 29144457290     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000193472.22117.26     Document Type: Article

References (20)

1. Harbott J, Viehmann S, Borkhardt A, et al. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
2. Ford AM, Fasching K, Panzer-Grümayer ER, et al. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL/AML1 fusion genes. Blood. 2001;98:558-564.
3. Attarbaschi A, Mann G, König M, et al. Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia. 2004;18:1811-1816.
4. Lanza C, Volpe G, Basso G, et al. Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia. Br J Haematol. 1997;97:460-462.
5. Raynaud SD, Dastugue N, Zoccola D, et al. Cytogenetic abnormalities associated with the t(12;21): a collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia. Leukemia. 1999;13:1325-1330.
6. Heerema NY, Sather HN, Sensel MG, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:1537-1544.
7. Kees UR, Burton PR, Lü C, et al. Homozygous deletions of the p16/MTS1 gene in pediatric acute leukemia is associated with unfavorable clinical outcome. Blood. 1997;11:4161-4166.
8. INK4A deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 2001;97:572-574.
9. Heerema NA, Harbott J, Galimberti S, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18:693-702.
10. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.
11. Kim DH, Moldwin RL, Vignon C, et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood. 1996;88:785-794.
12. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer. 1999;35:1941-1953.
13. Schmitt CA, McCurrach ME, de Stanchina E, et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13:2670-2677.
14. Andreasson P, Hoglund M, Bekassy AN, et al. Cytogenetic and FISH studies of a single-center consecutive series of 152 childhood acute lymphoblastic leukemias. Eur J Haematol. 2000;65:40-51.
15. Rubnitz JE, Behm FG, Pui CH, et al. Genetic study of childhood acute lymphoblastic leukemia with emphasis on p16, MLL and ETV6 abnormalities: results of St. Jude Total Therapy Study XII. Leukemia. 1997;11:1201-1206.
16. Nomdedéu JF, Badell I, Estivill C, et al. TEL rearrangements in acute lymphoblastic leukemia: association with p16 deletions in relapsed cases. Haematologica. 2001;86:547-548.
17. Anguita E, González FA, López J, et al. TEL/AML1 transcript and p16 gene deletion in a patient with childhood acute lymphoblastic leukemia. Br J Haematol. 1997;99:240-241.
18. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitors INK4 family genes p 15, p6, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
19. INK4a immunocytochemistry in adult ALL with standard risk karyotype. Leukemia. 2001;15:1054-1059.
20. Dalle JH, Fournier M, Nelken B, et al. p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood. 2002;99:2620-2623.